KRYSTAL BIOTECH INC.

Krystal Biotech Receives European Commission Orphan Designation for KB407 for the Treatment of Cystic Fibrosis

18 Jan 2023 07:00:00 By Nasdaq GlobeNewswire

Krystal Biotech Announces FDA’s 3-Month Extension of BLA PDUFA Date and Regulatory Update for B-VEC to Treat Patients with Dystrophic Epidermolysis Bullosa

09 Jan 2023 08:00:01 By Nasdaq GlobeNewswire

New England Journal of Medicine Publishes Phase 3 Data on B-VEC in Patients with Dystrophic Epidermolysis Bullosa

14 Dec 2022 17:00:00 By Nasdaq GlobeNewswire

Jeune Aesthetics to Participate in the Cantor Fitzgerald Medical and Aesthetic Dermatology, Ophthalmology and Medtech/Diagnostic Conference

05 Dec 2022 07:00:00 By Nasdaq GlobeNewswire

Krystal Biotech to Present at BofA Securities 2022 Biotech SMID Cap Conference

01 Dec 2022 07:00:00 By Nasdaq GlobeNewswire

Krystal Biotech to Present at 5th Annual Evercore ISI HealthCONx Conference

23 Nov 2022 07:00:00 By Nasdaq GlobeNewswire

Jeune Aesthetics Announces Positive Durability Results for KB301 in the PEARL-1 Extension Cohort, an Investigational Gene-based Treatment for Improvement of Fine Lines and Wrinkles

17 Nov 2022 07:00:01 By Nasdaq GlobeNewswire

Krystal Biotech Announces Third Quarter 2022 Financial Results and Operational Highlights

07 Nov 2022 07:00:01 By Nasdaq GlobeNewswire

Krystal Biotech to Present at Chardan’s 6th Annual Genetic Medicines Conference

29 Sep 2022 07:00:00 By Nasdaq GlobeNewswire

Krystal Biotech Receives Positive Opinion from EMA Pediatric Committee on the Pediatric Investigation Plan for B-VEC for the treatment of Dystrophic Epidermolysis Bullosa

21 Sep 2022 16:30:00 By Nasdaq GlobeNewswire

Krystal Biotech to Present at H.C. Wainwright 24th Annual Global Investment Conference

08 Sep 2022 07:00:00 By Nasdaq GlobeNewswire

FDA Accepts Krystal Biotech’s Biologics License Application for Dystrophic Epidermolysis Bullosa

18 Aug 2022 17:00:00 By Nasdaq GlobeNewswire

Krystal Biotech Announces Second Quarter 2022 Financial Results and Reports Updates on Operational Progress

08 Aug 2022 07:00:00 By Nasdaq GlobeNewswire

Krystal Biotech Announces FDA Acceptance of KB407 IND Application for Cystic Fibrosis Clinical Trial

01 Aug 2022 18:39:37 By Nasdaq GlobeNewswire

Krystal Biotech to Present at William Blair Biotech Focus Conference 2022

06 Jul 2022 07:00:00 By Nasdaq GlobeNewswire

Krystal Biotech Submits Biologics License Application to U.S. FDA Seeking Approval of B-VEC for the Treatment of Patients with Dystrophic Epidermolysis Bullosa

22 Jun 2022 07:00:01 By Nasdaq GlobeNewswire

Krystal Biotech Submits Biologics License Application to U.S. FDA Seeking Approval of B-VEC for the Treatment of Patients with Dystrophic Epidermolysis Bullosa

22 Jun 2022 07:00:01 By Nasdaq GlobeNewswire

Krystal Biotech to Present at Goldman Sachs 43rd Annual Global Healthcare Conference

07 Jun 2022 07:00:00 By Nasdaq GlobeNewswire

Krystal Biotech to Present Additional Data on B-VEC from the GEM-3 Phase 3 Study at the Society for Investigative Dermatology Annual Meeting

19 May 2022 19:30:00 By Nasdaq GlobeNewswire

Krystal Biotech Announces First Quarter 2022 Financial Results and Reports Updates on Operational Progress

09 May 2022 16:15:00 By Nasdaq GlobeNewswire